Bridgefront Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Bridgefront Capital’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$382K	Buy	+6,564	New	+$302K	0.09%	327

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bridgefront Capital's XENE Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2026: 6,564 shares worth $382K. The stake represents 0.09% of the portfolio and ranks #327 among its holdings.

290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

Bridgefront Capital held 6,564 shares of Xenon Pharmaceuticals worth $382K as of Q1 2026.
Xenon Pharmaceuticals was a new Bridgefront Capital position in Q1 2026.
Xenon Pharmaceuticals made up 0.09% of Bridgefront Capital's portfolio in Q1 2026, its #327 holding.
290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.